Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008176 | 0.88 | KMT2A (0.44) | L3MBTL1ITGB3ITGA2BKMT2AMEN1 | |
| SCHEMBL2014794 | 0.86 | L3MBTL1 (0.40) | L3MBTL1TSHRTDP1EPHX2 | |
| SCHEMBL2011176 | 0.84 | ITGB3 (0.54) | L3MBTL1TSHRTDP1ITGB3ITGA2B | |
| SCHEMBL2007999 | 0.79 | GAA (0.44) | L3MBTL1TSHRTDP1KMT2AMEN1 | |
| SCHEMBL2009704 | 0.78 | L3MBTL1 (0.52) | L3MBTL1TSHRTDP1ITGB3ITGA2B | |
| SCHEMBL2013251 | 0.77 | GAA (0.39) | L3MBTL1TSHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2012807 | 0.76 | NPC1 (0.44) | L3MBTL1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2007940 | 0.76 | NPC1 (0.42) | L3MBTL1TSHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12413739 | 0.74 | MEN1 (0.44) | TSHRTDP1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL17953131 | 0.73 | L3MBTL1 (0.55) | L3MBTL1TSHRTDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-1677783-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | Nicholas Piramal India Limited (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005035495-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | L3MBTL1 4640/4885TSHR 163/4885TDP1 3983/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | L3MBTL1 4640/4885TSHR 163/4885TDP1 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.